Journey Medical (DERM) to Release Earnings on Monday

Journey Medical (NASDAQ:DERM - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect Journey Medical to post earnings of ($0.24) per share and revenue of $12.05 million for the quarter.

Journey Medical (NASDAQ:DERM - Get Free Report) last released its earnings results on Wednesday, March 26th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.22) by $0.30. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%. The company had revenue of $14.30 million for the quarter, compared to analyst estimates of $14.21 million. On average, analysts expect Journey Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Journey Medical Stock Performance

NASDAQ DERM opened at $7.03 on Monday. The company has a 50-day simple moving average of $6.15 and a two-hundred day simple moving average of $5.36. Journey Medical has a 12-month low of $3.20 and a 12-month high of $7.84. The firm has a market cap of $162.42 million, a price-to-earnings ratio of -7.48 and a beta of 0.86. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81.

Analyst Ratings Changes

DERM has been the topic of a number of analyst reports. Industrial Alliance Securities set a $10.50 price objective on shares of Journey Medical in a research report on Thursday, March 27th. Alliance Global Partners reaffirmed a "buy" rating on shares of Journey Medical in a research note on Thursday, March 27th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Journey Medical presently has a consensus rating of "Buy" and a consensus price target of $9.88.

Insiders Place Their Bets

In other Journey Medical news, CEO Claude Maraoui sold 49,271 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $5.01, for a total value of $246,847.71. Following the completion of the transaction, the chief executive officer now directly owns 2,003,147 shares in the company, valued at $10,035,766.47. This represents a 2.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 105,831 shares of company stock worth $536,622 over the last three months. 13.16% of the stock is currently owned by company insiders.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.